Meda Shirisha, Freund Nadja, Norman Kevin J, Thompson Britta S, Sonntag Kai-C, Andersen Susan L
Laboratory of Developmental Neuropharmacology, McLean Hospital, Harvard Medical School, USA.
Experimental and Molecular Psychiatry, Ruhr-University, Germany.
Heliyon. 2019 Aug 23;5(8):e02254. doi: 10.1016/j.heliyon.2019.e02254. eCollection 2019 Aug.
Microinjections, lesions, viral-mediated gene transfer, or designer receptors exclusively activated by designer drugs (DREADDs) can identify brain signaling pathways and their pharmacology in research animals. Genetically modified animals are used for more precise assessment of neural circuits. However, only a few of the gene-based pathway modifications are available for use in outbred rat strains.
Behaviorally characterized Sprague-Dawley rats undergo tract tracing through microinjection of fluorospheres, followed by laser capture microdissection (LCM) and qPCR for detecting mRNA of pathway-associated gene products. Correlations between mRNA expression and behavior identify specific involvement of pharmacologically relevant molecules within cells of interest. Here, we examined this methodology in an impulsive choice paradigm and targeted projections from the orbital and medial prefrontal cortex.
In this proof of concept study, we demonstrate relationships between measures of impulsive choice with distinct neurotransmitter receptor expression in cell populations from four different signaling pathways.
Combining behavior, tract tracing, LCM, and gene expression profiling provides more cellular selectivity than localized lesions and DREADDs, and greater pharmacological specificity than microinjections and viral-mediated gene transfer due to targeting identified neurons. Furthermore, the assessment of inter-individual pathways provides insight into the complex nature of underlying mechanisms involved in typical and atypical behavior.
The novel combination of behavior, tract tracing, LCM, and single gene or potential whole genome transcriptome analysis allows for a more targeted understanding of the interconnection of neural circuitry with behavior, and holds promise to identify more specific drug targets that are relevant to behavioral phenotypes.
在实验动物中,微量注射、损伤、病毒介导的基因转移或仅由设计药物激活的设计受体(DREADDs)可用于识别脑信号通路及其药理学特性。基因修饰动物用于更精确地评估神经回路。然而,只有少数基于基因的通路修饰可用于远交系大鼠。
对行为特征明确的斯普拉格-道利大鼠进行荧光球微注射追踪神经束,随后进行激光捕获显微切割(LCM)和定量聚合酶链反应(qPCR)以检测通路相关基因产物的信使核糖核酸(mRNA)。mRNA表达与行为之间的相关性确定了感兴趣细胞内药理学相关分子的具体参与情况。在此,我们在冲动选择范式中检验了该方法,并以眶额皮质和内侧前额叶皮质的投射为靶点。
在这项概念验证研究中,我们证明了冲动选择测量与来自四种不同信号通路的细胞群体中不同神经递质受体表达之间的关系。
结合行为、神经束追踪、LCM和基因表达谱分析比局部损伤和DREADDs具有更高的细胞选择性,并且由于靶向已识别的神经元,比微量注射和病毒介导的基因转移具有更高的药理学特异性。此外,对个体间通路的评估有助于深入了解典型和非典型行为所涉及潜在机制的复杂本质。
行为、神经束追踪、LCM以及单基因或潜在的全基因组转录组分析的新组合,能够更有针对性地理解神经回路与行为的相互联系,并有望识别出与行为表型相关的更具体的药物靶点。